Switzerland · Delayed Price · Currency is CHF BioVersys AG Statistics
Total Valuation
BioVersys AG has a market cap or net worth of CHF 130.97 million. The enterprise value is 57.15 million.
| Market Cap | 130.97M |
| Enterprise Value | 57.15M |
Important Dates
The next estimated earnings date is Thursday, December 11, 2025.
| Earnings Date | Dec 11, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
BioVersys AG has 5.85 million shares outstanding.
| Current Share Class | 5.85M |
| Shares Outstanding | 5.85M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 3.13% |
| Owned by Institutions (%) | 9.64% |
| Float | 4.29M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 100.06 |
| PB Ratio | 1.87 |
| P/TBV Ratio | 1.87 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -2.95 |
| EV / Sales | 43.66 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -3.42 |
Financial Position
The company has a current ratio of 9.24, with a Debt / Equity ratio of 0.26.
| Current Ratio | 9.24 |
| Quick Ratio | 9.02 |
| Debt / Equity | 0.26 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.09 |
| Interest Coverage | -17.32 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -20.96% |
| Revenue Per Employee | 45,138 |
| Profits Per Employee | -667,517 |
| Employee Count | 27 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 25.61 |
| 200-Day Moving Average | 31.62 |
| Relative Strength Index (RSI) | 43.62 |
| Average Volume (20 Days) | 3,014 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BioVersys AG had revenue of CHF 1.31 million and -19.36 million in losses. Loss per share was -4.34.
| Revenue | 1.31M |
| Gross Profit | 1.31M |
| Operating Income | -17.71M |
| Pretax Income | -19.36M |
| Net Income | -19.36M |
| EBITDA | -17.65M |
| EBIT | -17.71M |
| Loss Per Share | -4.34 |
Balance Sheet
The company has 92.07 million in cash and 18.25 million in debt, giving a net cash position of 73.82 million or 12.63 per share.
| Cash & Cash Equivalents | 92.07M |
| Total Debt | 18.25M |
| Net Cash | 73.82M |
| Net Cash Per Share | 12.63 |
| Equity (Book Value) | 69.88M |
| Book Value Per Share | 11.97 |
| Working Capital | 84.08M |
Cash Flow
In the last 12 months, operating cash flow was -16.67 million and capital expenditures -43,000, giving a free cash flow of -16.71 million.
| Operating Cash Flow | -16.67M |
| Capital Expenditures | -43,000 |
| Free Cash Flow | -16.71M |
| FCF Per Share | -2.86 |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -1,353.25% |
| Pretax Margin | -1,478.84% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
BioVersys AG does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -14.78% |
| FCF Yield | -12.76% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BioVersys AG has an Altman Z-Score of 4.04 and a Piotroski F-Score of 1.
| Altman Z-Score | 4.04 |
| Piotroski F-Score | 1 |